Venous thromboembolism (VTE) is a frequent complication in melanoma patients with brain metastases (BM). The management of these patients is challenging because of the high risk of intracranial hemorrhage (ICH) and the limited data available on the safety of anticoagulation in this scenario. We reviewed the treatments and outcomes among melanoma patients with BM and VTE at our institution to determine the safety of anticoagulation in these patients. A retrospective chart review was performed to identify melanoma patients with BM who were diagnosed with VTE. The clinical characteristics of the BM and the VTE, the treatments given for VTE, subsequent ICH, and overall survival (OS) were determined. The characteristics and outcomes were compared between patients who received systemic anticoagulation and those who did not. A total of 74 evaluable melanoma patients with BM and VTE were identified. Fifty-seven (77%) patients received systemic anticoagulation. There was no significant difference in the number (P = 0.40) or the maximum diameter (P = 0.55) of brain metastasis between the patients who received anticoagulation and those who did not. Two (4%) patients who received anticoagulation developed ICH, which was not statistically different from the patients who did not receive anticoagulation (0%, P = 1.00). There was a trend toward longer OS from VTE among patients who received systemic anticoagulation (median OS: 4.2 vs. 1.2 months, P = 0.06). Anticoagulation for VTE did not significantly increase the risk of ICH or decrease OS in patients with melanoma BM. These data support the safety of systemic anticoagulation for VTE in these patients.
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Introduction
The incidence of melanoma is increasing. In 2011, an estimated 70 230 patients were diagnosed with melanoma, and 8790 patients died from this disease, in the USA [1] . Melanoma has a high risk of metastasizing to the central nervous system (CNS). Melanoma is the third most common source of brain metastases (BM), exceeded only by lung and breast cancer. As breast and lung cancer are much more common, these data indicate the high proclivity of melanoma to metastasize to the brain [2] . Up to 75% of patients with stage IV melanoma develop brain involvement, and such patients have a median survival of B4 months [3] .
Venous thromboembolism (VTE) is a common phenomenon in cancer patients. It is estimated that 4-20% of cancer patients will develop VTE, and it is an important cause of cancer-related mortality [4, 5] . The risk of VTE is particularly high in patients with brain tumors [6] . Mechanical treatments for VTE, such as inferior vena cava (IVC) filters, are prone to complications, particularly in patients with hypercoaguable conditions such as cancer. Thus, systemic anticoagulation, either with low-molecular-weight heparin (LMWH) or with vitamin-K antagonists, is generally recommended for patients with VTE [7] . However, this therapy does result in a risk of hemorrhage, which can be particularly devastating when it occurs intracranially. Thus, the management of VTE in patients with BM represents a common and challenging clinical scenario.
The management of VTE in patients with BM from melanoma is particularly challenging because of the significant risk of hemorrhage in BM from this disease [8, 9] . Little data are available on the relative risk of intracranial hemorrhage (ICH) in melanoma patients with BM receiving anticoagulation. To develop rational management approaches for these patients, we reviewed the clinical characteristics and outcomes of metastatic melanoma patients with BM who were diagnosed with VTE to determine the relative risk and benefits of systemic anticoagulation in these patients.
Methods

Patients
Under an IRB-approved protocol, we reviewed the records of patients treated in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center from 1 June 1996 to 30 June 2006. Patients who had radiographic evidence of parenchymal brain involvement at the time of diagnosis of a VTE, including deep venous thrombosis (DVT) or pulmonary embolism (PE), were selected. For each patient, data were collected on pre-existing characteristics (medical comorbidities, presence of extracranial metastases); the number, maximal size, and hemorrhage of intraparenchymal brain lesions; the type of VTE (DVT, PE, both) and clinical presentation (clinically suspected, incidental finding, or symptomatic); treatments provided for VTE, including IVC filter placement and the type and dose of systemic anticoagulation; and the occurrence of hemorrhagic events (intracranial, extracranial) and overall survival (OS) after the diagnosis of VTE. For patients who received anticoagulant therapy for PE, subsequent radiographic imaging was reviewed for VTE resolution.
Statistical analysis
Fisher's exact test was used to assess the association between categorical variables and the use of systemic anticoagulation in patients with VTE, and between the on-study outcomes of ICH and extracranial hemorrhage. The method of Kaplan and Meier was used to estimate the distribution of OS from the date of the VTE event, and distributions were compared between groups using the log-rank test. All statistical tests were performed two sided, and no adjustment was made for the multiplicity of testing.
Results
Patient characteristics and treatments for venous thromboembolism
Eighty-one patients with melanoma BM who were diagnosed with VTE were identified. Seven of these patients had undergone surgical resection of their BM within a week of the VTE event, and thus could not be evaluated for the subsequent risk of ICH. The clinical characteristics at the time of diagnosis of the VTE of the 74 evaluable patients are shown in Table 1 . Seventy (95%) of the patients had concurrent extracranial disease and 46 (62%) had at least one medical comorbidity. Six patients (8%) were receiving prophylactic anticoagulation at the time of diagnosis of VTE for atrial fibrillation (n = 3), postsurgical care (n = 1), cellulitis in the lower extremity (n = 1), and chronic PE (n = 1).
Fifty-seven (77%) of the evaluable patients received systemic anticoagulation for VTE. There was no significant difference between those patients who received anticoagulation and those who did not in the prevalence of medical comorbidities (P = 0.78), extracranial disease (P = 1.00), or the antecedent use of prophylactic anticoagulation (P = 1.00) ( Table 1) . Among the patients who received anticoagulation, 37 (65%) had one to four BM, whereas 20 (35%) had more than four; this distribu-tion was not significantly different from the patients who did not receive anticoagulation (P = 0.40) ( Table 1) . Thirty-one (61%) of the patients who received systemic anticoagulation had a maximum intracranial tumor diameter of greater than 1 cm, which was similar to the patients who did not receive anticoagulation (71%, P = 0.55). There was also no significant difference in the location of the largest intracranial lesion between the two groups of patients (P = 0.94). There was evidence of intratumoral hemorrhage at the time of diagnosis of VTE in 21 (28%) of the 74 patients overall; 14 of these patients were subsequently treated with systemic anticoagulation and seven were not (P = 0.22). Nineteen of the patients were diagnosed with only a PE, 25 with only DVT, and 30 with both PE and DVT ( Table 2 ). The type (P = 0.57) and clinical presentation (P = 0.66 for PE, P = 0.97 for DVT) of VTE also showed no significant differences between patients who did and did not receive systemic anticoagulation.
Among the 57 patients who received anticoagulation, 26 were treated with systemic anticoagulation alone, whereas 31 also underwent IVC filter placement (Table 3) . Among the patients who did not receive anticoagulation, 13 had an IVC filter, and four were offered only supportive measures because of extensive disease and/or decline in status. The most common anticoagulant used was enoxaparin, which was given at a full dose (1 mg/kg subcutaneously every 12 h or 1.5 mg/kg subcutaneously every 24 h) in six patients and at a reduced dose (0.5 mg/kg subcutaneously every 12 h or 1 mg/kg once daily) in 41 patients. Fifteen of the patients treated with reduced-dose enoxaparin had radiographically diagnosed pulmonary emboli that were re-evaluated after B6 weeks of anticoagulation; all 15 showed radiographic resolution of their thrombi.
Bleeding events
The median follow-up for the evaluable patients from the diagnosis of VTE was 3.4 months (range: 0.3-30.3). Among the 74 patients who were diagnosed with VTE with BM from melanoma, 10 patients died within 1 month without interval CNS imaging. Three of these patients were receiving anticoagulation and seven were not. The cause of death for all three patients who were receiving systemic anticoagulation was extensive progressive disease; there were no clinical findings to suggest intracranial or extracranial bleeding events at the time of death. All of the remaining patients (n = 64) underwent subsequent CNS imaging after the diagnosis of VTE, and were considered evaluable for the analysis of the risk of bleeding events. For the patients with ICH at the time of VTE diagnosis, images were reviewed for evidence of new or worsening hemorrhage.
Six patients developed a hemorrhagic event subsequent to the diagnosis of VTE ( Table 4 ). Two of these events were intracranial, whereas four were extracranial. Both episodes of ICH (2/64 patients with CNS imaging) occurred in patients who had received systemic anticoagulation and Anticoagulation for VTE with brain metastases Alvarado et al. 311
did not have evidence of ICH when VTE was diagnosed. The overall incidence of ICH in the patients who received anticoagulation (4%) did not differ significantly from those who did not (0%, P = 1.0). One patient with two BM (maximum diameter 1.4 cm) developed asymptomatic ICH after 3 weeks of a low dose of LMWH, and survived over 12 months after the ICH. The second patient who developed ICH had numerous intracranial lesions (at least 10; maximum diameter 6.1 cm), had been diagnosed at an outside facility with DVT, and was treated with coumadin for 1 week before transferring to our center for a partial seizure, ICH, and prolonged International Normalized Ratio (INR). The patient had altered mental status with clinical evidence of significant disease progression and died a few days later. Extracranial bleeding events occurred in two (4%) patients receiving anticoagulation and two (12%) who did not, which was also not significantly different (P = 0.22). Three of the extracranial bleeding events occurred in patients who had evidence of intratumoral hemorrhage in their BM at the time of VTE diagnosis. Two of these patients received anticoagulation (enoxaparin); none of the three patients had worsening or new ICH.
Survival
All 74 patients with VTE and BM were included in the analysis of survival from VTE diagnosis (median OS = 3.4 months). The patients who received anticoagulation had a median survival of 4.2 months from the diagnosis of VTE. The patients who did not receive anticoagulation had a median survival of 1.2 months (P = 0.06 vs. anticoagulated) ( Fig. 1 ). In agreement with previous studies, patients with more than four BM (median OS = 2.6 months) had significantly shorter survival than patients with four or less BM (5.4 months, P = < 0.0001). The number of BM also correlated with survival from VTE among the patients receiving systemic anticoagulation (2.6 months for 1-4 BMs vs. 5.9 months for >4 BMs, P = < 0.0001) ( Table 5 ). Neither the size of the largest BM (P = 0.80) nor the existence of hemorrhage (P = 0.23) at the time of VTE correlated significantly with survival. There was a significant (P = 0.002) association of survival with the location of the largest BM, with the worst outcomes observed with temporal lobe BMs (median = 1.1 months) and longer survival with frontal (5.3 months) and parietal lobe (5.1 months) BMs.
Discussion
Epidemiologic data show that the incidence and mortality of melanoma have increased markedly over the last 50 years [10] . Similarly, there has been a dramatic increase in the annual incidence of brain metastasis across all cancers, possibly reflecting the increased efficacy of therapies to control extracranial metastases [11] . However, such therapies often fail to prevent the development of BM and the mortality attributable to these tumors. The management of VTE in melanoma patients with BM is a challenging and increasingly common clinical scenario.
In this single-center retrospective study, we observed a 4% incidence of ICH with the use of systemic anticoagulation in melanoma patients with known BM. This rate is relatively low, and did not differ significantly from the rate of ICH in VTE patients who did not receive systemic anticoagulation. In addition, there was no evidence that VTE patients with melanoma BM who received systemic anticoagulation had shorter survival from the diagnosis of VTE than patients who did not.
To our knowledge, this represents the first analysis of the risk of ICH among patients with melanoma BM treated with systemic anticoagulation. The results of this study are similar to previous reports on the use of anticoagulation in patients with primary brain tumors. Among a large cohort of patients with high-grade gliomas, ICH developed in two of 103 (1.9%) patients who were diagnosed with VTE and treated with unfractionated heparin (UFH), followed by warfarin, which was almost identical to the ICH rate (2.2%) among the glioma patients without VTE and not receiving anticoagulation [12] . The majority of bleeding events in the UFH cohort in that study occurred in the setting of supratherapeutic levels of anticoagulation [13] [14] [15] . The safety of warfarin for longterm use was evaluated in 22 patients with malignant gliomas, none of whom developed ICH [16] . However, the use of a long-acting vitamin K antagonist requires very close monitoring, with regular follow-ups, and a wellinformed patient who can maintain a relatively stable diet. Drug interactions with medications that are commonly used in patients with BM (i.e. anticonvulsants, certain antibiotics, cimetidine) can lead to fluctuations in the intensity of anticoagulation and requires careful assessment. As with UFH, hemorrhagic complications associated with the use of warfarin frequently occur in the context of overcoagulation [17] . Over the last decade, clinical trials have showed superior efficacy and equivalent safety for LWMH in the prevention of recurrent VTE events in cancer patients [18, 19] . Supported by these data, the majority of the melanoma patients in our cohort were treated with enoxaparin, an LMWH that is effective and approved for use in patients with DVT and PE. The recommended dosing of enoxaparin for the treatment of VTE is 1 mg/kg Overall survival (months) 20 25 30
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subcutaneously twice a day or alternatively 1.5 mg/kg once a day. Our patients were treated with either of these dosages at the treating-physician's discretion, but this did not affect the outcomes.
The similar rate of ICH observed in our cohort of patients with BM from melanoma with that reported previously in patients with gliomas is reassuring, but not necessarily expected. Although there are a number of studies that indicate that the vasculature of tumors is different from that of normal tissue, there is also evidence that the vasculature of BM may be quite different from primary brain tumors. The vasculature of BM appears to be different from primary brain tumors in their expression of specific proteins (i.e. P-glycoprotein), and some studies have reported that histologically, the vessels of BM retain features of the vasculature of the primary tumors from which they originate [20, 21] . In addition, mechanical disruption could result from the penetration of metastatic tumor cells through the vascular endothelium of the CNS, which is required for the establishment of BMs, and could thus increase the risk of ICH. Functional differences between the vasculature of primary and metastatic brain tumors are also suggested by demonstrated differences in the penetration of paclitaxel in the periphery of tumors and the surrounding normal tissues in patients who were administered this agent immediately before craniotomy [22] .
We acknowledge that the retrospective nature of this study results in several limitations in the analysis performed. Although we did not identify significant differences in the number, maximal size, or presence of hemorrhage in the intracranial metastases between the patients who did and did not receive anticoagulation, the short median survival after VTE diagnosis among the patients who did not receive anticoagulation suggests that other factors (i.e. hospice referral, poor performance status) could have contributed to, or correlated with, their poor outcomes. Thus, we cannot be sure that the groups of patients who did and did not receive anticoagulation were fully equivalent/balanced. However, even without this comparator group, the relatively low incidence (4%) of ICH among the patients who received anticoagulation is reassuring. This in fact is much lower than the prevalence of ICH hemorrhage that was detected at the time of VTE diagnosis in this cohort of patients (28%), which is similar to the prevalence of hemorrhage (34.6%) reported in a cohort of 355 melanoma patients with BM at the Memorial Sloan Kettering Cancer Center [23] . The confirmation of a lack of ICH, or a lack of worsening of existing ICH, by CNS imaging in 55 of the 57 patients supports the likelihood of this low risk with anticoagulation; in turn, we acknowledge that the risk of ICH could be underestimated in the patients who did not receive anticoagulation in this cohort because of the rapid deaths of seven of those patients without CNS imaging. We also acknowledge that conclusions about the safety of systemic anticoagulation in melanoma patients with BM are limited by the nonuniformity of the regimens used in this retrospective cohort. However, the safety data from the 41 patients treated with enoxaparin at a total dose of 1 mg/kg/ day, which was effective for resolving pulmonary emboli in 15 of 15 evaluated patients, indicate that this is a reasonable regimen to consider for such patients. Definitive conclusions about safety would require a randomized trial. Finally, although we observed no difference in the risk of bleeding between patients with a maximum BM diameter of less than 1 (n = 24) versus greater than 1 cm (n = 41), we note that very few patients in this cohort had large BMs (three patients, 1-2 cm; 12 patients, 2-3 cm; three patients, >3 cm). Thus, the relative risk of systemic anticoagulation in melanoma patients with large (> 3 cm) BMs remains to be defined.
In summary, the emergence of more effective therapies in melanoma, and the growing availability of clinical trials for patients with CNS involvement, supports the need for an improved understanding of the risk factors for ICH in these patients. This information will be important not only for clinical management but also for the interpretation of clinical events observed in trials. Our data indicate that systemic anticoagulation can be used safely in melanoma patients with VTE with small (< 3 cm) BM, on the basis of the prevalence of ICH and survival observed in this retrospective cohort of patients. However, additional data from other sites with large populations of melanoma patients and/or randomized trials of systemic anticoagulation will be necessary for definitive conclusions.
